泰素每周用药加卡铂与每3周用药加卡铂治疗老年非小细胞肺癌临床观察  

A clinical observation on combination chemotherapy of taxol administration weekly and carboplatin vs.taxol administration every 3 weeks and carboplatin for the senile patients with non-small cell lung cancer

作　　者：殷铁军[1] 王素芳[1] 胡长耀[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院,武汉430030

出　　处：《肿瘤》2004年第3期300-302,共3页Tumor

摘　　要：目的　比较泰素 (Taxol)每周用药加卡铂 (CBP)与泰素每 3周用药加卡铂方案在老年非小细胞肺癌化疗中的安全性、疗效及对生存质量影响。方法　将 4 2例老年非小细胞肺癌患者随机分为两组 ,每组 2 1例 ,A组患者采用泰素每周用药方案 :泰素 70mg/m2 d1、d8、d15 ;卡铂 (AUC =5 ,areaunderthecurve)d2 ,每 5周重复 ;B组患者采用泰素每 3周用药方案 :泰素 135mg/m2 d1;卡铂 (AUC =5 )d2 ,每 3周重复。每位患者至少接受 2周期上述方案化疗。结果　A组与B组相比较 ,毒副反应相似 ,仅中性粒细胞Ⅲ /Ⅳ级毒副反应的发生率统计学差异有显著性意义 ( 5 0 .0 0 %、2 5 .0 0 % ,χ2 =8.0 0P <0 .0 0 5 ) ;有效率分别为 6 1.90 % ( 13/2 1)、33.33% ( 7/2 1) ,但统计学差异无显著性意义 ( χ2 =3.4 4 ,P >0 .0 5 ) ;两组患者生存质量ECOG评分均有下降 ,差异无显著意义 ,( χ2 =1.88,P >0 .0 5 )。结论　泰素每周用药加卡铂与泰素每 3周用药加卡铂治疗老年非小细胞肺癌 ,结果前者疗效稍好 ,但毒副反应稍重 。Objective To determine which combination chemotherapy scheme, taxol administration weekly with carboplatin or. Taxol administration every 3 weeks with carboplatin, was favorable for the senile patients with non small cell lung cancer by a case control study. Methods Forty two cases of senile patients with non small cell lung cancer had been randomly divided into two groups:the patients in group A had received taxol 70 mg/m 2 d1,8,15, carboplatin (AUC=5,area under the concentration time curve) d2 every 5 weeks, while the patients in group B had received taxol 135mg/m2 d1, carboplatin (AUC=5) d2 every 3 weeks. The patients in group A and those in group B were comparable. Each patient at least had received 2 cycles of chemotherapy. The response rates, the side effect and the quality of life were compared before and after treatment. Results Compared the patients in group A and those in group B, the incidence of granulocytopenia with grade 3/4 was much different 50.00 % vs. 25.00 % (χ 2= 8.00 P <0.005). The incidence and proportion of the other side effect were relatively the same. Zero of 42 cases was CR (complete response) and 13 cases were PR (partial response) in group A, 7 cases were PR in group B. The total response rate was 61.90 %(13/21)vs. 33.33 %(7/21), but there was no significance (χ 2= 3.44, P > 0.05 ). ECOG score had slightly reduced in two groups, but there is no difference between two groups (χ 2=1.88, P >0.05). Conclusions Compared taxol administration weekly with carboplatin and taxol administration every 3 weeks and carboplatin for the senile patients with non small cell lung cancer, the total response rate of the former chemotherapy scheme is slightly high and the side effects were slightly severe. Both combination chemotherapy schemes have a little disadvantage on the quality of life.

关 键 词：泰素 卡铂 联合化疗 老年人 非小细胞肺癌 临床观察 生存质量 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]